在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

MYC Monoclonal Antibody

  • 中文名稱:
    MYC鼠單克隆抗體
  • 貨號(hào):
    CSB-MA015270A0m
  • 規(guī)格:
    ¥1320
  • 圖片:
    • Western Blot
      Positive WB detected in: Hela whole cell lysate
      All lanes: MYC antibody at 1:500
      Secondary
      Goat polyclonal to mouse IgG at 1/50000 dilution
      Predicted band size: 49, 51 KDa
      Observed band size: 49 KDa
      Exposure time:5min
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    MYC單克隆抗體(CUSABIO貨號(hào):CSB-MA015270A0m)是專為科研領(lǐng)域開發(fā)的靶向檢測(cè)工具,針對(duì)人類MYC原癌基因編碼的調(diào)控蛋白進(jìn)行精準(zhǔn)識(shí)別。作為細(xì)胞周期調(diào)控和腫瘤發(fā)生的關(guān)鍵因子,MYC蛋白在多種癌癥研究中具有重要價(jià)值。本產(chǎn)品采用小鼠IgG1亞型單抗,通過重組人源MYC全長蛋白(1-439氨基酸)免疫制備,液體形態(tài)便于實(shí)驗(yàn)操作,建議在-20°C或-80°C條件下長期保存以確保穩(wěn)定性。經(jīng)嚴(yán)格驗(yàn)證可在Western Blot和ELISA實(shí)驗(yàn)中展現(xiàn)優(yōu)異性能,適用于腫瘤機(jī)制研究、基因表達(dá)調(diào)控分析及信號(hào)通路探索等科研場景。該抗體未經(jīng)標(biāo)記處理,保留天然抗原結(jié)合能力,12個(gè)月有效期內(nèi)批次一致性穩(wěn)定,為癌癥生物學(xué)、分子病理學(xué)等基礎(chǔ)研究提供可靠工具,助力MYC相關(guān)蛋白功能解析和疾病模型構(gòu)建。
  • 產(chǎn)品名稱:
    Mouse anti-Homo sapiens (Human) MYC Monoclonal antibody
  • Uniprot No.:
  • 基因名:
  • 別名:
    AU016757 antibody; Avian myelocytomatosis viral oncogene homolog antibody; bHLHe39 antibody; c Myc antibody; Cellular myelocytomatosis oncogene antibody; Class E basic helix-loop-helix protein 39 antibody; MGC105490 antibody; MRTL antibody; Myc antibody; Myc protein antibody; Myc proto oncogene protein antibody; Myc proto-oncogene protein antibody; myc-related translation/localization regulatory factor antibody; MYC_HUMAN antibody; Myc2 antibody; myca antibody; MYCC antibody; Myelocytomatosis oncogene a antibody; Myelocytomatosis oncogene antibody; Niard antibody; Nird antibody; oncogene c-Myc antibody; Oncogene Myc antibody; OTTHUMP00000158589 antibody; OTTHUMP00000227763 antibody; Proto-oncogene c-Myc antibody; Protooncogene homologous to myelocytomatosis virus antibody; RNCMYC antibody; Transcription factor p64 antibody; Transcriptional regulator Myc-A antibody; V-Myc avian myelocytomatosis viral oncogene homolog antibody; v-myc myelocytomatosis viral oncogene homolog (avian) antibody; zc-myc antibody
  • 宿主:
    Mouse
  • 反應(yīng)種屬:
    Human
  • 免疫原:
    Recombinant Human MYC protein (1-439AA)
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標(biāo)記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    IgG1
  • 純化方式:
    >95%, Protein G purified
  • 克隆號(hào):
    5H5G5
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產(chǎn)品提供形式:
    Liquid
  • 應(yīng)用范圍:
    ELISA, WB
  • 推薦稀釋比:
    Application Recommended Dilution
    WB 1:500-1:5000
  • Protocols:
  • 儲(chǔ)存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能:
    Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells. Functions with TAF6L to activate target gene expression through RNA polymerase II pause release.
  • 基因功能參考文獻(xiàn):
    1. the findings of this study demonstrate that hsamiR24 suppresses metastasis in nasopharyngeal carcinoma by regulating the cMyc/EMT axis, suggesting that hsamiR24 may be used as a prognostic factor and as a novel target for the prevention of nasopharyngeal carcinoma metastasis. PMID: 30226609
    2. lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells by up-regulating c-myc and TGF2BP1 expression. PMID: 30119193
    3. we demonstrate that neither MYC IHC nor MYC FISH alone is a sufficient screening mechanism for identification of the clinically relevant entities of HGBLwR or DEL PMID: 28868942
    4. Because RPL23 is encoded by a target gene of c-Myc, the RPL23/Miz-1/c-Myc regulatory circuit provides a feedback loop that links efficient RPL23 expression with c-Myc's function to suppress Miz-1-induced Cdk inhibitors and thereby leads to apoptotic resistance in higher-risk myelodysplastic syndrome patients. PMID: 28539603
    5. GATAD2B interacts with C-MYC to enhance KRAS driven tumor growth. PMID: 30013058
    6. low expression of c-Myc protein predicts poor outcomes in patients with HCC with hepatectomy. PMID: 29690860
    7. Combined, these findings suggest that c-Myc could transcriptionally regulate TCRP1 in cell lines and clinical samples and identified the c-Myc-TCRP1 axis as a negative biomarker of prognosis in tongue and lung cancers. PMID: 28623290
    8. Kazakh and Han patients with esophageal squamous cell carcinoma with Glut1 c-myc co-expression had poorer prognosis. PMID: 29629851
    9. MYC activation in papillary clear cell renal cell carcinoma leads to a worse prognosis. PMID: 28593993
    10. could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in classical Hodgkin lymphoma PMID: 29708579
    11. Fluorescence in situ hybridization studies (histologic sections) confirmed translocations of MYC (8q24), BCL2 (18q21) and BCL6 (3q27) in all patients. PMID: 30043475
    12. topical mevastatin accelerates wound closure by promoting epithelialization via multiple mechanisms: modulation of GR ligands and induction of the long noncoding RNA Gas5, leading to c-Myc inhibition. PMID: 29158265
    13. CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151
    14. Data suggest that MYC induction of REV-ERBalpha is both persistent and recurrent across many inducible MYC model systems. PMID: 28332504
    15. HUWE1 overexpression could functionally suppress prostate carcinoma development both in vitro and in vivo, possibly by inverse regulation of c-Myc. PMID: 29966975
    16. Menin functions as an oncogenic regulatory factor that is critical for MYC-mediated gene transcription. PMID: 28474697
    17. High c-myc expression is associated with colorectal cancer. PMID: 30015962
    18. Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. PMID: 29654697
    19. FBP1 modulates the sensitivity of pancreatic cancer cells to BET inhibitors by decreasing the expression of c-Myc. These findings highlight FBP1 could be used as a therapeutic niche for patient-tailored therapies PMID: 30201002
    20. miR135a directly bound to UCA1 and the 3' untranslated region of cmyc, and UCA1 competed with cmyc for miR135a binding. PMID: 30015867
    21. MYC directly regulates DANCR and plays important role in cancer cell proliferation. PMID: 29180471
    22. In this review, we provide support to the hypothesis that the cooperation of c-Myc with transcriptional cofactors mediates c-Myc-induced cellular functions. We produce evidence that recently identified cofactors are involved in c-Myc control of survival mechanisms of cancer cells PMID: 30261904
    23. 4-chlorobenzoyl berbamine (CBBM) inhibits the JAK2/STAT3 pathway, leading to reduced c-Myc transcription. Collectively, these findings suggest that CBBM could be a promising lead compound for treatment of c-Myc-driven diffuse large B cell lymphoma. PMID: 30099568
    24. Results revealed that C-MYC protein is highly expressed in colon cancer tissues, mainly in the cell nucleus and was identified as a direct target for mir-184. C-MYC appeared to participate in cell cycle regulation and malignant transformation to colon cancer. PMID: 28782841
    25. MACC1 and c-Myc are highly expressed in serum and tumor tissues of EC patients. Both are correlated with TNM stage, primary infiltration, and lymph node or distal metastasis. PMID: 29984790
    26. study provides an interesting example using chemical biological approaches for determining distinct biological consequences from inhibiting vs. activating an E3 ubiquitin ligase and suggests a potential broad therapeutic strategy for targeting c-MYC in cancer treatment by pharmacologically modulating cIAP1 E3 ligase activity. PMID: 30181285
    27. The data demonstrated that 10058F4, a cMyc inhibitor, increased the growth inhibition, G0/G1 phase arrest and apoptosis of the NALM6 and CEM cells as induced by dexamethasone (DXM), a type of GC. PMID: 29749488
    28. c-MYC/BCL2 protein co-expression is associated with non-germinal center B-cell in Diffuse Large B-Cell Lymphoma PMID: 29801406
    29. c-Myc was capable of upregulating HP1gamma by directly binding to the E-box element in the first intron of HP1gamma gene, and the upregulated HP1gamma, in turn, repressed the expression of miR-451a by enhancing H3K9 methylation at the promoter region of miR-451a. PMID: 28967902
    30. A subset of pancreatic acinar cell carcinomas shows c-MYC alterations including gene amplification and chromosome 8 polysomy. PMID: 29721608
    31. Expression and Clinical Significance of LC-3 and P62 in Non-small Cell Lung Cancer PMID: 29945702
    32. The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1alpha expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment. PMID: 29625108
    33. a novel signal circuit of Stat3/Oct-4/c-Myc was identified for regulating stemness-mediated Doxorubicin resistance in triple-negative breast cancer PMID: 29750424
    34. MYC amplification and MYC overexpression occurred almost exclusively in secondary cutaneous angiosarcoma in our series. PMID: 29135507
    35. High c-myc expression is associated with the development of prostate cancer. PMID: 29554906
    36. Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. PMID: 29698681
    37. Authors conclude that quantitative measurements of intratumor heterogeneity by multiplex FISH, detection of MYC amplification and TP53 mutation could augment prognostication in breast cancer patients. PMID: 29181861
    38. PCYT1A was upregulated by MYC, which resulted in the induction of aberrant choline metabolism and the inhibition of B-lymphoma cell necroptosis. PMID: 28686226
    39. Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas. PMID: 28665415
    40. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression. PMID: 29666157
    41. High MYC amplification is associated with HER2 positive breast cancers in African American women. PMID: 29523126
    42. These data suggest that MYC acts as a master coordinator that inversely modulates the impact of cell cycle and circadian clock on gene expression via its interaction with MIZ1. PMID: 27339797
    43. In our study, the c-myc oncogene was amplified in 11.1% of BPH samples. Bivariate analysis failed to reveal any significant association between oncogene amplification and the clinicopathologic variables examined. PMID: 29234244
    44. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF1A and HIF1B binding to a MYC enhancer. PMID: 27774982
    45. Data indicate that miR-34a enhanced the sensitivity to cisplatin by upregulation of c-Myc and Bim pathway. PMID: 29060932
    46. Luciferase reporter assay showed that c-Myc, an oncogene that regulating cell survival, angiogenesis and metastasis, was a direct target of miR-376a. Over-expression of miR-376a decreased the mRNA and protein levels of c-Myc in A549 cells. PMID: 28741879
    47. The present findings show that expression of c-MYC has prognostic value in squamous cell carcinoma of the tongue, and could be useful in choice of therapy. PMID: 28393404
    48. Multivariable analysis indicated that IPI (P = 0.002), chemotherapy regimens (P = 0.017), and MYC gene rearrangements (P = 0.004) were independent adverse prognostic factors for all diffuse large B cell Lymphoma(DLBCL) patients in this study. Results demonstrated that the poor survival of DLBCL patients with HBV infection was closely involved in chemotherapy regimens, IPI, and MYC gene rearrangements PMID: 29209623
    49. MYC extra copy in diffuse large B-cell lymphoma is an independent poor prognostic factor PMID: 28776574
    50. The c-Myc/miR-200b/PRDX2 loop regulates colorectal cancer (CRC) progression and its disruption enhances tumor metastasis and chemotherapeutic resistance in CRC. PMID: 29258530

    顯示更多

    收起更多

  • 相關(guān)疾病:
    Burkitt lymphoma (BL)
  • 亞細(xì)胞定位:
    Nucleus, nucleoplasm. Nucleus, nucleolus.
  • 數(shù)據(jù)庫鏈接:

    HGNC: 7553

    OMIM: 113970

    KEGG: hsa:4609

    STRING: 9606.ENSP00000367207

    UniGene: Hs.202453



主站蜘蛛池模板: 又粗又硬又黄又爽的视频永久| 国产av激情无码久久| 四库影院永久国产精品| 亚洲国产一成人久久精品| 国产一区国产二区在线精品| 久9热视频这里只精品18| 狠狠88综合久久久久综合网| 高h纯肉无码视频在线观看| 亚洲暴爽av天天爽日日碰| 亚洲精品第一国产综合国服瑶| 国产精品喷浆| 亚洲 精品 综合 精品 自拍| 天美传媒精品1区2区3区| 亚洲男人的天堂成人www| 久久精品女人天堂av免费观看| 亚洲人成亚洲人成在线观看| 艳妇臀荡乳欲伦交换在线播放| 天天影视网天天综合色| 亚洲国产丝袜精品一区| 欧美牲交a欧美牲交aⅴ免费| 豆国产96在线 | 亚洲| 精品久久欧美熟妇www| 成人免费乱码大片a毛片 | 丰满多毛的陰户视频| 亚州中文字幕午夜福利电影| 少妇系列之白嫩人妻| 成人伊人亚洲人综合网站| 中文字幕久久精品一区二区三区| 亚洲中文字幕无码久久| 中文在线最新版天堂| 欧美成aⅴ人高清怡红院| 国产亚洲久久久久久久| 欧美xxxxx高潮喷水| 欧美变态暴力牲交videos| 18禁裸男晨勃露j毛网站| 天干夜天干天天天爽视频| 大肉大捧一进一出好爽mba| 久久视频这里有精品33| 日韩在线 | 中文| 成人无码精品1区2区3区免费看| 娇小萝被两个黑人用半米长|